Lightnews — Scholar-powered news

Reposted by Maine-Anjou AAV-GN Research Group

Benoît Brilland @benoitbrilland.bsky.social · Sep 9

Using kidney transcriptomics, we identified a robust 12-gene signature predicting renal survival in #ANCA #vasculitis, outperforming histopathology, and opening the way to precision medicine. Thank you for the highlight @asnpublications.bsky.social !

ASN Publications @asnpublications.bsky.social · Aug 11

Large-scale kidney transcriptomics identified a 12-gene signature, including CLU and C3, predicting kidney failure in ANCA-associated vasculitis. Read more in #ASNJASN: kidney.pub/JASN0779

@benoitbrilland.bsky.social

1 4

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Jun 10

Outstanding review that outlines evolving #ANCA #vasculitis treatments: from B-cell therapies (obinutuzumab, CAR-T) and T-cell therapies (ustekinumab) to new comers (T-cell engagers, alternative-pathway inhibitors, antifibrotics, ANCA–antigen blockers). A must read! www.nature.com/articles/s41...

2

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Apr 25

Ex vivo #CRISPR-Cas9 knock out PR3 autoantigen in HSPCs prevents PR3-ANCA-driven neutrophil activation while preserving immune function. While aHSCT would still be required, this opens the door to sustained, drug-free remission in PR3 #ANCA #vasculitis! doi.org/10.1016/j.ki... @kidneyint.bsky.social

1

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Apr 1

Targeting endothelial ferroptosis protects kidneys in #ANCA -associated #vasculitis, while systemic inhibition increases inflammation. This is why cell-specific therapies should be prioritised over blanket treatments! @kidneyint.bsky.social doi.org/10.1016/j.ki...

2 1

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Apr 1

Link to study: www.nature.com/articles/s41...

Anti-myeloperoxidase IgM B cells in anti-neutrophil cytoplasmic antibody-associated vasculitis - Nature Communications

The etiology of autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is still poorly understood. Here the authors associate anti-myeloperoxidase (MPO) IgM-express...

www.nature.com

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Apr 1

1️⃣ Biomarker: IgM levels could signal early disease activity (relapse prediction?).
2️⃣ Therapeutic: new strategies may focus on eliminating autoreactive IgM B cells (CAR-T?).
3️⃣ Mechanistic: uncovering IgM’s role offers clues to triggers of autoreactivity and flares.

1

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Apr 1

This new study shifts the focus from anti-MPO IgG to IgM in #ANCA -associated #vasculitis. IgM autoantibodies not only trigger potent complement activation but also dominate the autoreactive memory B cell pool—revealing a new pathogenic paradigm. Potential implications ⬇️

1 1 1

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Mar 24

Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Our analysis from the french REIN registry ⬇️

kireports.bsky.social @kireports.bsky.social · Mar 18

Kidney #Transplantation Improves Survival in Antineutrophil Cytoplasmic Antibody–Associated #ANCA #Vasculitides With End-Stage Kidney Disease #ESKD

#VisualAbstract by @DrPSVali

www.kireports.org/ar...

@benoitbrilland.bsky.social

1 2

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Jan 9

Last one: IV methylpred in very severe (eGFR<10 ml/min) #ANCA #vasculitis. Retrospective Chinese study, N=106, mostly MPO, high MMF use. IVMP (vs. no): higher dialysis independence (37% vs. 7%) & nearly significant lower mortality (19% vs. 37%, p = .056). bmcnephrol.biomedcentral.com/articles/10....

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Jan 9

IV methyl pred in severe (sCr > 500 or dialysis) #ANCA #vasculitis (observ.): no benefit for survival or renal recovery at M12. Higher risks of infections & diabetes with IVMP. Lower doses (1.5g total), more severe patients, MPO/PR3 more balanced than ⬇️. bmcnephrol.biomedcentral.com/articles/10....

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Jan 9

IV methylpred in "severe" #ANCA #vasculitis (observational study, target trial emulation): 1.0 g/day reduced 48-week mortality without increasing serious infections. 0.5 g/day showed limited effect. Limits: quite small number of subjects (201), mostly MPO. academic.oup.com/rheumatology...

1

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Jan 8

PEXIVAS post-hoc: no effect of reduced GC dose on kidney recovery in #ANCA #vasculitis. Faster kidney recovery with PLEX but not sustained beyond 3 months (better for subgroup GFR 15-30?). Real PLEX effect vs convection effect? @kronbichlerlab.bsky.social www.kidney-international.org/article/S008...

1 4

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Jan 7

66% of #ANCA #vasculitis patients have coronary artery calcification (CAC score>0), indicating high cardiovascular risk, especially in MPO+. Only 25% are on statins. Urgent need for better screening and tailored cardiovascular prevention. rmdopen.bmj.com/content/11/1...

1 4

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Jan 6

Infection is the top cause of death in #ANCA -associated #vasculitis, mostly during remission. Death certificates misreport causes, linking EHRs improves accuracy. We need to reduce infection risks through better immunosuppressive therapies www.sciencedirect.com/science/arti...

1

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 17

In #ANCA #vasculitis, 27% patients rated their health better or worse (≥ 20 PGA points) than their physicians did. This discordance highlights the need to address patients' perspectives to improve communication, shared decision-making, and care outcomes. pubmed.ncbi.nlm.nih.gov/39671122/

1 1

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 16

This study (aacrjournals.org/cancerimmuno...) shows that, in tumor-bearing mice, C5aR blockade boosts anti-PD1 efficacy by enhancing #antitumor immunity. Could these benefits translate to reducing long-term treatment-related adverse events in our #ANCA #vasculitis patients?

The C5a/C5aR1 axis promotes migration of tolerogenic dendritic cells to lymph nodes, impairing the anticancer immune response

Abstract. The precise mechanisms by which the complement system contributes to the establishment of an immunosuppressive tumor microenvironment (TME) and promotes tumor progression remain unclear. In ...

aacrjournals.org

1 4

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 12

@kronbichlerlab.bsky.social @kireports.bsky.social

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 12

First AI-driven model for grading #ANCA -associated #glomerulonephritis lesions achieves 93% accuracy. Grad-CAM heatmaps align with pathologists’ focus, enhancing prognosis reliability. Bonus: the heatmaps look like colorful PET scans of glomeruli! www.kireports.org/article/S246...

1 4 6

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 11

@sethirenalpath.bsky.social @kireports.bsky.social

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 11

In #ANCA-associated renal #vasculitis, higher percentage of normal glomeruli in kidney biopsy predicts lower rates of ESKD. Maybe good for AI implementation, but… performance vs. standard classifications (Berden, AKRiS) and beyond 1 year unknown. www.kireports.org/article/S246...

DEFINE_ME

www.kireports.org

1

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 10

Infections affect >50% of #ANCA -associated #vasculitis patients, with risk factors including diabetes, ESKD, kidney/lung involvement and treatment (methylprednisolone pulses, CYC, PLEX). Main site: respiratory system. Early risk management is crucial. doi.org/10.1016/j.au...

Redirecting

doi.org

1 4

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 5

Brace yourself, next Vasculitis Workshop is coming! Key dates:
✅ Abstract submission: 28 March - 19 September 2025
✅ Workshop dates: 21 - 25 February 2026
📍 Melbourne, Australia
vasculitis-melbourne2026.com

IVW 2026 | 22nd International Vasculitis Workshop

Join the 22nd International Vasculitis Workshop, a leading event dedicated to advancing research, treatment, and understanding of vasculitis. Connect with global experts, researchers, and practitioner...

vasculitis-melbourne2026.com

2 2

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 3

Abatacept RCT vs placebo (on top of oral GC) in relapsing non severe granulomatosis #GPA #vasculitis (ABROGATE study): non superiority of abatacept. Relapse/worsening in 62% vs 68%. No difference in any secondary end-point (and SAEs). Dr. C. Langford #ACR24 acrabstracts.org/abstract/a-r...

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Dec 2

Results of the TAPIR trial: glucocorticoid discontinuation in GPA #ANCA vasculitis.
▶️ higher number of relapse at 6 months for the discontinuation group
▶️ but driven by minor relapses and by subgroup not treated but Rituximab.
Presented by Pr. Peter Merkel #ACR24 (acrabstracts.org/abstract/a-m...)

1 1

Maine-Anjou AAV-GN Research Group @maineanjoureg.bsky.social · Nov 26

Reduced GC dose in #ANCA vasculitis: @terrierben.bsky.social confirms PEXIVAS results in real life: no difference in death/ESKD. Larger composite criteria [see table] (that may be discussed) in favor of standard GC dose, especially for RTX patients and severe AKI ard.bmj.com/content/earl...

5 5